Premium
Bitolterol Mesylate: A Beta‐adrenergic Agent; Chemistry, Pharmacokinetics, Pharmacodynamics, Adverse Effects and Clinical Efficacy in Asthma
Author(s) -
Walker Susannah B.,
Kradjan Wayne A.,
Bierman C. Warren
Publication year - 1985
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1985.tb03410.x
Subject(s) - theophylline , medicine , bronchodilator , asthma , pharmacology , cardiotoxicity , pharmacodynamics , b2 receptor , drug , pharmacokinetics , mesylate , adrenergic , adverse effect , anesthesia , chemotherapy , receptor , chemistry , bradykinin , organic chemistry
Bitolterol, (3–4 diester colterol) is a new β 2 ‐adrenergic agonist. Since it in itself is biologically inactive, bitolterol is considered a pro‐drug. When administered it is activated within the lung by esterase hdyrolysis to the active compound colterol catecholamine N ‐t‐butyl‐arterenol). In preclinical and clinical studies to date, bitolterol has proved to be an effective bronchodilator for adult and pediatric patients with chronic stable asthma and for some with chronic obstructive pulmonary disease. Bitolterol has been compared with other β 2 agents, including isoproterenol, metaproterenol and albuterol. There is no evidence for cardiotoxicity when bitolterol is used in combination with theophylline in human studies. It is effective for control of exercise‐induced asthma.